SCHEMBL3890675

SCHEMBL3890675

CCC(C)C(=O)N(C)Cc1ccc(-c2ccncc2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.49
LMNA P02545 2/20 0.47
ABHD6 Q9BV23 2/20 0.43
MGLL Q99685 1/20 0.41
HRH3 Q9Y5N1 1/20 0.40
ROCK2 O75116 2/20 0.40
MMP13 P45452 2/20 0.40
MMP12 P39900 1/20 0.40
ROCK1 Q13464 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
MAPT P10636 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CHRM2 P08172 1/20 0.38
CHRM4 P08173 1/20 0.38
CHRM5 P08912 1/20 0.38
CHRM1 P11229 1/20 0.38
CHRM3 P20309 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3879474 0.80 HPGD (0.55) HPGDLMNAMMP13TDP1MEN1
SCHEMBL3885499 0.78 HPGD (0.50) HPGDLMNAHRH3TDP1MEN1
SCHEMBL24316291 0.77 HPGD (0.50) HPGDLMNAMMP13TDP1CYP2C9
SCHEMBL3892129 0.77 RAB9A (0.50) ABHD6ROCK2ROCK1KMT2APPID
SCHEMBL13947891 0.72 HPGD (0.45) HPGDLMNAMMP13TDP1CYP2C9
SCHEMBL27619110 0.70 HRH3 (0.74) LMNAHRH3ROCK2MAPTCYP3A4
SCHEMBL17887964 0.70 MAPT (0.47) HPGDLMNATDP1MAPTCYP1A2
SCHEMBL19210473 0.69 MMP13 (0.53) HPGDLMNAROCK2MMP13ROCK1
SCHEMBL28842466 0.69 RIPK1 (0.46) HPGDLMNATDP1MEN1KMT2A
SCHEMBL9347698 0.68 RAB9A (0.50) MMP13KMT2ATSHRHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7592345-B2 Piperazine and [1,4]diazepan derivatives as NK antagonists HOFFMANN-LA ROCHE INC. (US) 2009-09-22 US disclosed
US-20080312216-A1 PIPERAZINE AND [1,4]DIAZEPAN DERIVATIVES AS NK ANTAGONISTS HOFFMANN-LA ROCHE, INC. 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312216-A1 PIPERAZINE AND [1,4]DIAZEPAN DERIVATIVES AS NK ANTAGONISTS DRD3, KCND3, GRIN3A HPGD 2069/4885LMNA 4076/4885ABHD6 4317/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.